The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO) are closely monitoring the current, acute shortages of cisplatin and carboplatin in the United States. ASCO has developed guidance for clinicians who are navigating the situation and offered recommendations to policymakers to help mitigate the current shortages and prevent similar situations in the future.
ASCO has a dedicated drug shortages website that will be kept up to date as information on the availability of drugs in shortage is released from the Food and Drug Administration (FDA). The site also offers clinician resources and links to more information.
We strongly encourages our members to report drug shortages directly to FDA. While the agency is aware of critical shortages, it is important that it receives these reports to better assess the scope of shortages and use in mitigation activities.
ASCO will remain in close contact with FDA and will also continue to share its concerns and recommendations with Congress. Use the ACT Network to urge lawmakers to take the organization’s recommended steps to mitigate drug shortages.
Bookmark asco.org/drugshortages to stay up to date on the current shortage of cancer drug treatments, as well as breaking news, advocacy, and analysis on cancer policy.